Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Egenix, Inc.
MILLBROOK, N.Y., June 4, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of William T. Nolan to its Corporate Advisory Committee.
Mr. Nolan has been an investment banker for over forty years specializing in corporate finance, turnarounds and securities sales. He began his career at Brown Brothers, Harriman & Company in New York and then held positions at Howard, Weil, Labouisse, Friedrichs & Co., Hill Samuel/Wood, MacKenzie & Co., Inc. and at S.G. Warburg & Co. Mr. Nolan has been CEO and CFO of several operating companies as part of the turnaround and restructuring process.
In 1989, he founded Devonshire Holdings, Inc. to assist small to mid-sized corporations in restructurings, buy-outs and financial reorganizations. Since its inception, Devonshire and its Partners have advised on and completed transactions ranging in size from $1,000,000 to $1,000,000,000 in Asia, Europe and North America.
Mr. Nolan is a graduate of Tulane University (BA) in Economics and the Harvard Business School (MBA) in International Finance. He is the author of the book entitled, The Wealth of Enterprises: A New Foundation for Economics & Management.
We at Egenix are delighted to have Mr. Nolan as a financial advisor and are confident he will make a significant contribution to the success of Egenix.
Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com
©2012 PR Newswire. All Rights Reserved.